C4 Therapeutics Stock Investor Sentiment

CCCC Stock  USD 6.38  0.08  1.24%   
About 71% of C4 Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that many traders are alarmed. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

C4 Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at www.macroaxis.com         
Disposition of 2250 shares by Kelly Schick of C4 Therapeutics subject to Rule 16b-3
Macroaxis News
3 days ago at www.macroaxis.com         
Disposition of 2250 shares by Siegel Jolie of C4 Therapeutics subject to Rule 16b-3
Macroaxis News
few days ago at globenewswire.com         
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Pro...
Macroaxis News: globenewswire.com
over a week ago at finance.yahoo.com         
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
Yahoo News
over a week ago at benzinga.com         
Why Summit Therapeutics Shares Are Trading Higher By Around 18 Here Are 20 Stocks Moving Premarket
benzinga news
over a week ago at globenewswire.com         
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Soc...
Macroaxis News: globenewswire.com
over a week ago at finance.yahoo.com         
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Soc...
Yahoo News
over two weeks ago at finance.yahoo.com         
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
Yahoo News
over two weeks ago at finance.yahoo.com         
C4 Therapeutics to Participate in Upcoming September Investor Conferences
Yahoo News
over two weeks ago at globenewswire.com         
Insider Trading
Macroaxis News: globenewswire.com
over three weeks ago at news.google.com         
Hennion Walsh Asset Management Inc. Makes New Investment in C4 Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three weeks ago at news.google.com         
BMO stock gets Outperform rating on C4 Therapeutics - Investing.com
Google News at Macroaxis
over a month ago at news.google.com         
C4 Therapeutics, Inc. Sees Significant Decrease in Short Interest - Defense World
Google News at Macroaxis
over a month ago at news.google.com         
C4 Therapeutics, Inc. Short Interest Update - MarketBeat
Google News at Macroaxis
over a month ago at finance.yahoo.com         
C4 Therapeutics Announces European Society for Medical Oncology Changed the Previously Accepted CFT1...
Yahoo News
Far too much social signal, news, headlines, and media speculation about C4 Therapeutics that are available to investors today. That information is available publicly through CCCC media outlets and privately through word of mouth or via CCCC internal channels. However, regardless of the origin, that massive amount of CCCC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of C4 Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of C4 Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to C4 Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive C4 Therapeutics alpha.

C4 Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Anderson Kenneth Carl of 2320 shares of C4 Therapeutics at 4.85 subject to Rule 16b-3
07/01/2024
2
Disposition of 6191 shares by Reyno Leonard of C4 Therapeutics at 5.0 subject to Rule 16b-3
07/10/2024
3
SG Americas Securities LLC Acquires Shares of 22,368 C4 Therapeutics, Inc. - Defense World
07/26/2024
4
CCCC Stock Earnings C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
08/01/2024
5
C4 Therapeutics Announces European Society for Medical Oncology Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presen...
08/14/2024
6
C4 Therapeutics, Inc. Sees Significant Decrease in Short Interest - Defense World
08/19/2024
7
Insider Trading
08/29/2024
8
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
09/10/2024
9
Disposition of 2250 shares by Siegel Jolie of C4 Therapeutics subject to Rule 16b-3
09/16/2024
10
Disposition of 2250 shares by Kelly Schick of C4 Therapeutics subject to Rule 16b-3
09/17/2024

Complementary Tools for CCCC Stock analysis

When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account